VLO
30
-6
PG
45
2
PM
50
5
HCA
35
-5
MDLZ
55
2
UNH
46
4
KMI
53
5
SBUX
49
2
PPL
52
2
MHK
46
12
CLX
53
2
WMT
60
-2
PSX
34
-6
BDX
46
11
AZO
48
5
NAVI
52
2
TMO
54
-2
CHD
59
-2
TRIP
50
-2
EQR
56
2
VLO
30
-6
PG
45
2
PM
50
5
HCA
35
-5
MDLZ
55
2
UNH
46
4
KMI
53
5
SBUX
49
2
PPL
52
2
MHK
46
12
CLX
53
2
WMT
60
-2
PSX
34
-6
BDX
46
11
AZO
48
5
NAVI
52
2
TMO
54
-2
CHD
59
-2
TRIP
50
-2
EQR
56
2
Financhill
Back

Cerevel Therapeutics Holdings 10K Form

Buy
67

CERE
Cerevel Therapeutics Holdings

Last Price:
42.16
Seasonality Move:
28.79%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CERE News And Ratings

See the #1 stock for the next 7 days that we like better than CERE

CERE Financial Statistics

Sales & Book Value

Annual Sales: $2.7M
Cash Flow: $-98.32M
Price / Cash Flow: 0
Annual Sales: $3.71
Price / Book: 11.36

Profitability

EPS (TTM): -2.67000
Net Income (TTM): $-432.84M
Gross Margin: $-2.5M
Return on Equity: 0%
Return on Assets: 0%

Cerevel Therapeutics Holdings Earnings Forecast

Key Cerevel Therapeutics Holdings Financial Ratios

  • The Gross Profit Margin over the past 6 years for CERE is -92.59%.
  • The Selling, General & Administrative Expenses for CERE have been equal to 588.89% of Gross Profit Margin.
  • The Interest Expense is -2.44% of Operating Income.
  • Per Share Earnings over the last 11 years have been positive in 5 years.

Cerevel Therapeutics Holdings Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CERE
Website: cerevel.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CERE Technical Analysis vs Fundamental Analysis

Buy
67
Cerevel Therapeutics Holdings (CERE) is a Buy

Is Cerevel Therapeutics Holdings a Buy or a Sell?